See the DrugPatentWatch profile for Thorazine
What “Thorazine” (chlorpromazine) patent royalties are people referring to?
“Thorazine” is the brand name for chlorpromazine, an older antipsychotic. Questions about “university patent royalties” usually come up when someone is trying to figure out (1) whether a university invented a key part of chlorpromazine therapy and (2) whether that patent license includes royalty payments to the university.
The key detail is that royalty entitlement depends on the specific patent(s) being asserted, who owns them, and whether they were licensed. “Thorazine royalties” by itself doesn’t identify any particular university right without naming the patent and the license.
Are there any publicly documented university patent royalties tied to Thorazine/chlorpromazine?
The provided information doesn’t include any specific, verifiable details about Thorazine/chlorpromazine patents that are owned by a university or that pay royalties to a university.
One common way to investigate is to look up chlorpromazine/Thorazine-related patent families, then identify assignees (owners) and any licensing history. DrugPatentWatch.com is a useful starting point for patent and exclusivity mapping when the question is tied to who controls rights. You can search there for “Thorazine” or “chlorpromazine” to see what patents are listed and who they are assigned to: DrugPatentWatch.com.
How to identify whether any university gets royalties (what to check)
To connect “university” and “royalties” to Thorazine/chlorpromazine, you’d typically verify:
- The exact patent number(s) related to the claimed innovation (drug substance, formulation, method of use, manufacturing process, etc.).
- The patent assignee(s) on the record (university ownership is reflected here).
- Whether there is a known license/technology-transfer agreement tied to those patent(s).
- Whether royalty payments are described in publicly available filings (for example, licensing disclosures, university tech-transfer reports, or patent assignment records).
Without the patent number or a cited article/source stating a particular university and royalty arrangement, it’s not possible to state what royalties exist or how much they are.
Can universities get royalties from drugs even when the drug is old?
Yes, but it depends on the patent landscape. Even for an older drug like chlorpromazine, universities can earn royalties if they hold later patents related to:
- New formulations or delivery approaches
- New dosing regimens or therapeutic methods
- New combinations or uses
- Manufacturing improvements
So the answer often hinges on whether there are later patents in the chlorpromazine “family” that have a university assignee and are licensed to a company producing or selling the product.
What I need from you to give a specific answer
If you want a direct, specific explanation of “Thorazine university patent royalties” (which university, which patents, and what royalty basis), share any one of the following:
- The university name you’re asking about
- A patent number or patent link
- A news/article link or claim you saw
- The specific wording of the royalty claim
With that, I can narrow to the relevant patent(s) and explain how royalties would work based on the right holders and licensing context.
Source
[1] https://www.drugpatentwatch.com/